Gilead Sciences (NASDAQ:GILD) Stock: Insider Daniel Patrick O’day Sells 9,810 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel O’Day sold 9,810 shares of Gilead Sciences stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $175.17, for a total transaction of $1,718,417.70. Following the sale, the chief executive officer directly owned 551,683 shares in the company, valued at approximately $96,638,311.11. The trade was a 1.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Wednesday, November 4th, Daniel O’Day sold 102,619 shares of Gilead Sciences stock. The stock was sold at an average price of $175.16, for a total value of $17,974,744.04.
• On Monday, November 2nd, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $169.74, for a total value of $2,546,100.00.
• On Friday, October 30th, Daniel O’Day sold 15,881 shares of Gilead Sciences stock. The stock was sold at an average price of $175.25, for a total value of $2,783,145.25.
• On Thursday, October 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $147.90, for a total value of $2,218,500.00.
• On Tuesday, September 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $148.64, for a total value of $2,229,600.00.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $166.89 on Friday. The firm has a market cap of $207.00 billion, a PE ratio of -52.81 and a beta of 0.35. The company has a quick ratio of 0.95, a current ratio of 1.38 and a debt-to-equity ratio of 1.84. Gilead Sciences, Inc. has a 52 week low of $116.88 and a 52 week high of $176.58. The business’s fifty day simple moving average is $153.04 and its 200-day simple moving average is $140.94.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The firm had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. During the same period last year, the company earned $2.47 EPS. The company’s quarterly revenue was up 6.8% on a year-over-year basis. Equities analysts forecast that Gilead Sciences, Inc. will post -1.07 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.0%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently -103.80%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. TD Cowen lifted their price objective on Gilead Sciences from $160.00 to $175.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Citigroup increased their target price on Gilead Sciences from $165.00 to $188.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Barclays lowered their target price on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a report on Wednesday, July 29th. JPMorgan Chase & Co. lifted their target price on Gilead Sciences from $170.00 to $190.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Finally, Bank of America boosted their price target on shares of Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a research note on Tuesday, October 20th. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $170.15.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Persistent Asset Partners Ltd acquired a new stake in Gilead Sciences in the 2nd quarter valued at about $25,000. Kimelman & Baird LLC acquired a new position in shares of Gilead Sciences during the second quarter worth about $25,000. PFS Partners LLC increased its stake in shares of Gilead Sciences by 101.1% during the third quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 96 shares during the period. Laurel Wealth Advisors LLC purchased a new stake in shares of Gilead Sciences during the third quarter worth approximately $29,000. Finally, Wiser Advisor Group LLC purchased a new stake in shares of Gilead Sciences during the second quarter worth approximately $30,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: New HIV-prevention data showed twice-yearly lenacapavir achieved nearly twice the one-year treatment persistence of daily oral F/TDF, a result that could support Gilead’s long-acting HIV-prevention strategy. Article: New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence
• Positive Sentiment: In the Phase 3 IDEAL study, Livdelzi (seladelpar) achieved ALP normalization in about 75% of participants with primary biliary cholangitis. The results may strengthen its case for broader second-line use, although the stock reportedly fell following the update. Article: Gilead’s Livdelzi Achieves 75% ALP Normalization
• Positive Sentiment: Recent third-quarter results beat analyst estimates for earnings and revenue, and Gilead raised full-year product-sales guidance. The company also maintained its quarterly dividend at $0.82 per share. Article: Did Earnings Beat Just Shift Gilead Sciences’ Investment Narrative?
• Neutral Sentiment: CEO Daniel O’Day sold more than 112,000 shares across November 4–5, but the transactions were conducted under a pre-arranged Rule 10b5-1 plan. He retained 551,683 shares, which may temper concerns about the sales. SEC Form 4 filing

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C.

Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.